Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA responds to pressure to approve COVID-19 vaccines

President Biden said he expected FDA approval by early autumn.

By Brian Buntz | August 2, 2021

FDA logoHealth experts have insisted that the FDA accelerate the approval process for COVID-19 vaccines, starting with the Pfizer-BioNTech vaccine. The agency will reportedly begin a “sprint” initiative to accelerate its approval of that vaccine, which was the first to win emergency use authorization, according to multiple media outlets, including The Wall Street Journal.

Media reports suggest that the agency is planning on approving the Pfizer-BioNTech vaccine by Labor Day or earlier.

New COVID-19 vaccinations continue to flag behind late-spring levels, although they have recently increased slightly with the rise of the Delta SARS-CoV-2 variant.

In early May, Pfizer Inc. (NYSE:PFE) and BioNTech SE (NSDQ:BNTX) began the rolling submission process with the FDA for a Biologics License Application (BLA) for their COVID-19 vaccine. On June 1, Moderna (NSDQ:MRNA) reached the same milestone.

In early July, FDA granted priority review to the Pfizer-BioNTech vaccine.

The agency has cleared the Pfizer-BioNTech and Moderna vaccines under its emergency use authorization program.

The lack of full FDA approval for COVID-19 vaccines has made it difficult for some organizations to mandate vaccination.

The act of expediting the full review of the Pfizer-BioNTech vaccine, however, will likely delay the agency’s attempts to ramp up site inspections and approve other therapies.

A May survey from KFF found that roughly one-third of vaccinated adults would be more likely to get vaccinated if FDA-approved COVID-19 vaccines were available.

FDA approval of the Pfizer vaccine would help boost vaccination rates, said Dr. Anthony Fauci in an interview with Reuters. Fauci is the director of the National Institute of Allergy and Infectious Diseases and chief medical adviser to the White House.

President Biden has said he anticipates COVID-19 vaccines to win full approval in early autumn.

Some employees facing vaccine mandates have suggested that such policies are illegal under 21 U.S.C. § 360bbb–3, which describes the authorization for medical products for use in emergencies.

Earlier this year, however, a federal judge denied a request for a temporary restraining order in one of the first lawsuits related to COVID-19 vaccine mandates.

Currently, nine states have passed laws to ban vaccine mandates. Some of those bans, however, apply only to vaccines that only have emergency use authorization.


Filed Under: Infectious Disease
Tagged With: BioNTech, coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccines, FDA, Moderna, Pfizer, vaccinations
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Secretary of Health removes all current members of the CDC advisory committee on immunization practices
covid-19 vaccine
FDA COVID booster pullback jolts vaccine stocks before gains cool
Coronavirus Covid-19 background - 3d rendering
Pregnancy associated with less long COVID: Researchers call for studies on protective biology
How technology advances are helping scientists unlock the mysteries of zoonotic diseases
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE